Prime Medicine, Inc.
PRME
$3.55
$0.3310.25%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.12M | 1.45M | 2.18M | 209.00K | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.12M | 1.45M | 2.18M | 209.00K | -- |
| Cost of Revenue | 3.22M | 2.86M | 34.10M | 40.34M | 4.22M |
| Gross Profit | -2.10M | -1.40M | -31.92M | -40.13M | -4.22M |
| SG&A Expenses | 13.12M | 13.28M | 12.30M | 14.10M | 12.60M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 54.49M | 53.85M | 46.41M | 54.44M | 55.67M |
| Operating Income | -53.38M | -52.39M | -44.22M | -54.23M | -55.67M |
| Income Before Tax | -52.59M | -51.89M | -42.28M | -52.52M | -55.46M |
| Income Tax Expenses | -- | -- | -- | -- | -134.00K |
| Earnings from Continuing Operations | -52.59M | -51.89M | -42.28M | -52.52M | -55.33M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -52.59M | -51.89M | -42.28M | -52.52M | -55.33M |
| EBIT | -53.38M | -52.39M | -44.22M | -54.23M | -55.67M |
| EBITDA | -51.51M | -50.69M | -42.51M | -52.67M | -54.13M |
| EPS Basic | -0.41 | -0.40 | -0.32 | -0.44 | -0.46 |
| Normalized Basic EPS | -0.25 | -0.24 | -0.20 | -0.28 | -0.29 |
| EPS Diluted | -0.41 | -0.40 | -0.32 | -0.44 | -0.46 |
| Normalized Diluted EPS | -0.25 | -0.24 | -0.20 | -0.28 | -0.29 |
| Average Basic Shares Outstanding | 129.19M | 130.88M | 130.92M | 119.76M | 119.19M |
| Average Diluted Shares Outstanding | 129.19M | 130.88M | 130.92M | 119.76M | 119.19M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |